Skip to main content

Table 5 Subgroup analysis for association of dexamethasone with discharge outcome in patients treated as bacterial meningitis at teaching hospitals in Ethiopia, 2011–2015

From: Adjunctive dexamethasone therapy in unconfirmed bacterial meningitis in resource limited settings: is it a risk worth taking?

Variables Death Low GOS
OR 95 % CI P OR 95 % CI P
Age
  < 50 years 3.08 1.74–5.48 <0.001* 2.83 1.79–4.48 <0.001*
  > = 50 years 4.00 1.19–13.46 0.025* 2.68 1.0–7.21 0.051
Duration of illness
  < =2 days 4.02 1.37–11.77 0.011* 2.05 0.94–4.50 0.072
  > 2 days 2.93 1.62–5.30 <0.000* 2.91 1.79–4.72 <0.001*
Level of conscious
 14 and 15 2.21 0.94–5.21 0.070 1.82 0.996 0.051
  < 14 3.69 1.84–7.40 <0.001* 388 20.3–7.44 <0.001*
HIV status
 Positive 3.25 0.46–22.93 0.237 18.00 1.63–198.51 0.018*
 Negative 3.38 1.91–5.66 <0.001* 2.49 1.63–3.80 <0.001*
Prior antibiotics
 Yes 3.59 1.24–10.38 0.018* 5.97 2.47–14.44 <0.001*
 No 3.04 1.68–5.50 <0.001* 2.07 1.30–3.29 0.002*
Focal neurologic deficit
 Yes 3.20 0.67–15.38 0.146 0.80 0.16–3.99 0.789
 No 3.00 1.72–5.23 <0.001* 2.77 1.80–4.29 0.003*
CSF appearance
 Turbid 2.72 0.67–11.11 0.163 2.44 0.79–7.51 0.121
 Clear 6.26 1.95–20.12 0.002* 4.28 2.14–8.58 <0.001*
TB suspected
 Yes 3.90 0.45–34.02 0.218 3.46 0.83–14.36 0.087
 No 3.09 1.79–5.34 <0.001* 2.18 1.40–3.39 0.001*
Diagnosis of meningitis
 Confirmed 1 1 1 1
 Probable 2.31 0.68–7.86 0.180 3.22 1.24–8.36 0.016*
 Suspected 3.38 1.73–6.59 <0.001* 2.09 1.16–3.75 0.014*
 Non-cases 6.98 1.50–32.56 0.013* 3.17 1.41–7.15 0.005*
  1. *Statistically significant